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Abstract
Background:  Bronchial  artery  embolisation  (BAE)  becomes  a  mainstay  in  the  treatment  of
hemoptysis.
Objective:  To  characterise  patients  with  hemoptysis  undergoing  bronchial  artery  angiography
(BAA) for  embolisation,  evaluating  outcomes.
Methods:  We  retrospectively  evaluated  patients  with  acute  severe  or  chronic  recurrent  hemopt-
ysis admitted  to  the  Pulmonology  department  and  submitted  to  BAA  for  purpose  of  embolisation.
Results: A  total  of  88  patients  were  submitted  to  BAA,  47  (53.4%)  were  male,  with  a  mean  age  of
61.4 ±  15.8  years.  In  64  (72.7%)  patients,  hemoptysis  presented  as  chronic  recurrent  episodes.
Hemoptysis  was  considered  severe  in  40  (45.5%)  patients.  Bronchiectasis  (other  than  cystic
ﬁbrosis) (n  =  35;  38.0%)  and  tuberculosis  sequelae  (n  =  31;  35.2)  were  the  major  aetiology  for
hemoptysis.  The  main  angiographic  abnormality  was  hypertrophy  and  tortuosity  (n  =  68;  77.3%).
BAE was  performed  in  67  (76.1%)  of  the  88  patients  submitted  to  BAA.  Immediate  success  was
achieved in  66  (98.5%)  patients.  Recurrence  of  hemoptysis  occurred  in  25  (37.3%)  patients,
and was  related  to  presence  of  shunting  (p  =  0.049).  The  procedure-related  complications  were
self-limited.
Conclusion:  Our  results  suggest  that  BAE  is  a  safe  and  effective  treatment  for  acute  severe
and chronic  recurrent  hemoptysis,  supporting  the  current  literature.  Besides  this,  bleeding
recurrence  was  relatively  high,  and  correlated  with  presence  of  systemic  pulmonary  shunting.
© 2015  Sociedade  Portuguesa  de  Pneumologia.  Published  by  Elsevier  España,  S.L.U.  All  rights
reserved.∗ Corresponding author.
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BT
l
c
n
n
t
i
m
t
p
t
t
b
a
g
a
a
e
a
w
c
p
a
t
a
e
s
S
T
S
W
t
w
R
A
m
p
l
identiﬁed  (Table  1).  Hemoptysis  presented  as  chronic  recur-
rent  episodes  in  64  (72.7%)  patients  and  as  a  ﬁrst  episode  in
24  (27.3%);  it  was  considered  severe  in  40  (45.5%)  patients.
Table  1  Other  non-pulmonary  risk  factors  for  hemoptysis.
Factors  n  (%)
Antiplatelet  drugs 12  (13.6)Bronchial  artery  embolisation  
Introduction
Hemoptysis,  deﬁned  as  the  expectoration  of  blood  from  the
lung  parenchyma  or  airways,  is  a  common  and  alarming  dis-
ease  symptom.1,2 The  circulation  in  the  lungs----one  of  the
richest  in  the  human  body----is provided  via  two  separate
vascular  systems:  the  pulmonary  and  bronchial  arteries.3
In  cases  of  severe  hemoptysis,  90%  of  the  blood  origi-
nates  from  the  bronchial  circulation,  5%  from  the  pulmonary
circulation  and  the  remaining  5%  from  the  non-bronchial
systemic  circulation.4,5 Hemoptysis  is  self-limiting  and  is
approached  effectively  with  conservative  management  in
most  cases.6 Nevertheless,  it  can  be  massive  and  life-
threatening  in  5--15%  of  cases,5 with  a  mortality  rate  of  more
than  50%  in  these  cases  if  not  treated  appropriately.7 The
currently  available  approaches  for  patients  with  hemopt-
ysis  are  conservative  medical  treatment,  bronchial  artery
embolisation  (BAE)  and  surgery.8,9 The  treatment  of  choice
depends  largely  on  the  severity  and  urgency  of  the
circumstances.
Bronchial  artery  angiography  (BAA)  with  BAE  is  a  min-
imally  invasive  procedure  that  has  become  a  mainstay
in  the  treatment  of  hemoptysis.10 It  consists  of  selective
bronchial  artery  catheterisation  and  angiography,  followed
by  embolisation  of  any  identiﬁed  abnormal  vessels  to  stop
the  bleeding.  It  has  been  used  in  patients  with  massive
and  recurrent  hemoptysis,11 but  rebleeding  can  emerge  as  a
problem  even  after  apparently  adequate  BAE.12,13
The  purpose  of  this  study  was  to  identify  and  to  char-
acterise  patients  with  hemoptysis  who  underwent  BAA  for
embolisation  in  our  centre  and  to  evaluate  their  long-term
outcomes.
Materials and methods
Patients
We  retrospectively  evaluated  88  consecutive  patients  admit-
ted  due  to  hemoptysis  to  the  pulmonology  department  of  a
university  and  to  a  tertiary  care  hospital,  between  January
2008  and  December  2013.  The  patients  all  underwent  BAA
for  embolisation  purposes.  The  criterion  for  referral  of  these
patients  for  BAE  was  an  acute  severe  hemoptysis,  as  deﬁned
below,  or  a  chronic  recurrent  hemoptysis  requiring  medical
attention.
The  information  on  blood  volume  expectorated  by
patients  was  limited;  consequently,  the  assessment  of  sever-
ity  was  based  on  clinical  criteria,  including  haematological
compromise  (a  haemoglobin  decrease  of  more  than  1  g),
haemodynamic  instability  (deﬁned  as  a  systolic  arterial  pres-
sure  less  than  90  mmHg)  and  respiratory  failure  (deﬁned  as
a  PaO2 less  than  60  mmHg).14
After  BAE,  immediate  success  was  deﬁned  as  the  absence
of  rebleeding  during  the  ﬁrst  month  after  BAE.  Recurrence
was  deﬁned  as  hemoptysis  occurring  after  BAE  and  requiring
medical  attention  (unscheduled  clinical  visits,  emergency
room  visits,  admission  or  repeated  BAE);  recurrence  was
categorised  according  to  timing  in  relation  to  the  initial  pro-
cedure  in  short-term  (within  1  month)  and  long-term  (more
than  1  month)  periods  after  BAE.35
ronchial  artery  embolisation
ransfemoral  bronchial  arteriography  was  performed  under
ocal  anaesthesia,  percutaneously  in  the  majority  of  the
ases,  using  a  4F  catheter.  Both  bronchial  arteries  and
on-bronchial  systemic  arteries  were  opaciﬁed.  The  diag-
ostic  angiographic  injections  were  always  selective  into
he  bronchial,  intercostal,  subclavian,  internal  mammary,
ntercostobronchial  and  inferior  phrenic  arteries,  using  a
icrocatheter  technique  with  a  2.7  F  Terumo  Progreat  as
he  standard  microcatheter.
Thoracic  aortograms  were  performed  mostly  on  those
atients  that  did  not  undergo  angio-CT  prior  to  embolisa-
ion,  in  order  to  delineate  the  number,  size  and  position  of
he  bronchial  arteries  and  to  check  for  aberrant  and  ectopic
ronchial  arteries.
Several  agents  were  used  for  embolisation:  polyvinyl
lcohol  (PVA)  particles,  PVA  hydrogel,  microcoils  and
elfoam,  alone  or  in  association,  depending  on  angiographic
bnormalities  (hypertrophy  and  tortuosity  of  bronchial
rteries,  hypervascularity,  parenchymal  staining,  contrast
xtravasation  and  arterioarterial  or  arteriovenous  shunting)
nd  the  Interventional  Radiologist’s  choice.  PVA  particles
ere  by  far  the  most  commonly  used  embolic  agents.  Micro-
oils  were  used  in  association  with  PVA  particles  only  in  two
atients,  with  hypertrophy,  hypervascularity  and  shunting
ngiographic  abnormalities.
Three  Interventional  Radiologists,  two  of  them  with  more
han  20  years  of  experience  in  bronchial  artery  embolisation
nd  the  other  one  with  more  than  10  years  of  experience  in
mbolisation  procedures  did  all  the  bronchial  artery  emboli-
ation  procedures.
tatistical  analysis
he  data  were  analysed  using  the  statistical  program  IBM
PSS  (Statistical  Package  for  Social  Sciences)  version  21.0  for
indows.  Differences  between  groups  were  analysed  using
he  chi-square  test  or  Fisher’s  exact  test.  A  p  value  <  0.05
as  considered  statistically  signiﬁcant.
esults
 total  of  88  patients  underwent  BAA; 47  (53.4%)  were
ale,  the  mean  age  was  61.4  ±  15.8  years,  and  38  (43.2%)
atients  had  a  smoking  history.  Apart  from  the  underlying
ung  disease,  additional  risk  factors  for  hemoptysis  wereCoagulation  disorders  12  (13.6)
Thrombocytopenia  11  (12.5)
Oral  anticoagulants  7  (8.0)
36  H.  Dabó  et  al.
Table  2  The  main  pulmonary  diseases.
Diseases  n  (%)
Bronchiectasis  35  (38.0)
Tuberculosis  sequelae  31  (35.2)
Chronic  pulmonary  aspergillosis  12  (13.6)
Pulmonary  tuberculosis  4  (4.5)
Lung  cancer  2  (2.3)
Arteriovenous  malformation  2  (2.3)
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Table  4  Complications  during  bronchial  artery
angiography.
Complications  n  (%)
Bronchial  artery  dissection  3  (3.4)
Chest  pain 3  (3.4)
(
i
(
r
w
o
o
p
a
s
p
a
d
6
a
ﬁ
D
I
e
o
v
s
c
s
r
i
b
o
h
i
c
sOthers  5  (5.5)
Unknown  7  (8.0)
Chest  CTs  (conventional  or  angiography)  were  available
efore  BAA  in  86  (97.7%)  patients,  and  showed  the  pos-
ible  causes  of  hemoptysis  in  81  (94.2%).  Eleven  (12.5%)
atients  had  thoracic  CT  angiography  obtained  less  than
ne  month  before  the  procedure.  Following  initial  stabili-
ation,  bronchoscopy  was  performed  in  53  (60.2%)  patients:
he  bronchoscopy  was  ﬂexible  in  50  (94.3%),  rigid  in  1  (1.9%)
nd  both  ﬂexible  and  rigid  in  2  (3.8%).  Bronchoscopy  could
dentify  the  bleeding  lobe  in  20  (37.7%)  patients,  and  endo-
copic  treatments  to  control  bleeding  were  attempted  in
 (15%)  of  these  patients,  using  cold  saline  instillation  and
opical  adrenaline.
As  shown  in  Table  2,  bronchiectasis  (other  than  that  asso-
iated  with  cystic  ﬁbrosis)  (n  =  35;  38.0%)  was  the  major
etiology  for  hemoptysis.  The  aetiology  could  not  be  iden-
iﬁed  in  7  (8.0%)  patients,  even  after  BAA.
BAA  was  performed  as  an  elective  procedure  in  72  (81.8%)
atients  and  as  an  urgent  or  life-saving  procedure  in  16
18.2%).  During  the  procedure,  the  left  bronchial  territory
as  explored  in  6  (6.8%)  patients,  the  right  bronchial  terri-
ory  in  19  (21.6%)  and  both  territories  in  63  (71.6%)  patients.
on-bronchial  systemic  collateral  arteries  were  systemati-
ally  explored  in  44  (50.0%)  patients.  The  main  angiographic
bnormality  was  combined  hypertrophy  and  tortuosity  in
8  (77.3%)  patients  (Table  3).  BAE  was  performed  in  67
76.1%)  of  the  88  patients  who  underwent  BAA;  BAE  was  per-
ormed  in  the  left  bronchial  territory  in  14  (20.9%)  patients,
ight  bronchial  territory  in  31  (46.3%)  and  both  territories
n  22  (32.8%).  Several  agents  were  used  for  embolisation:
olyvinyl  Alcohol  (PVA)  particles  (300--900  micron)  in  57
85.1%)  patients,  PVA  hydrogel  in  6  (9.0%),  PVA  particles  and
icrocoils  in  2  (3.0%),  PVA  particles  and  gelfoam  in  1  (1.5%)
nd  PVA  hydrogel  and  SpongostanTM in  1  (1.5%).  Immediate
uccess  was  achieved  in  66  (98.5%)  patients.  Despite  this,
ecurrence  occurred  in  25  (37.3%)  of  these  patients,  with
hort-term  recurrence  in  5  (7.5%)  and  long-term  recurrence
n  20  (29.8%).  The  median  time  to  recurrence  was  161  days
Table  3  Angiographic  signs  of  hemoptysis  during  bronchial
artery  angiography.
Signs  n  (%)
Hypertrophy  and  tortuosity  68  (77.3)
Hypervascularity  40  (45.5)
Shunting  36  (40.9)
Parenchymal  staining  13  (14.8)
Contrast  extravasation  2  (2.3)
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Hypersensitivity  reaction  to  contrast  media  1  (1.1)
1--955  days).  Of  all  clinical  and  radiological  features,  shunt-
ng  was  the  only  factor  favouring  recurrence  of  hemoptysis
p  =  0.049).  BAA  was  repeated  in  16  (23.9%)  patients  in  which
ecurrence  occurred  after  initial  BAE,  and  reembolisation
as  performed  in  15  (93.8%)  of  those  patients.  The  number
f  BAA  procedures  performed  per  patient  during  the  period
f  the  study  ranged  from  1  to  6.  Pulmonary  artery  angiogra-
hy  as  well  as  BAA  was  also  performed  in  6  (6.8%)  patients,
nd  2  (33.3%)  of  these  also  underwent  embolisation.
Procedure-related  complications  during  the  BAA  were
elf-limited  (Table  4).  During  the  hospital  stay,  surgery  was
erformed  in  3  (3.4%)  patients  despite  BAE  (2  lobectomies
nd  1  bilobectomy),  and  2  (2.3%)  patients  died  (one  of  them
ue  to  fulminant  bleeding).  A  total  of  58  (86.6%)  of  the
7  patients  who  underwent  BAE  were  eligible  for  follow-up
fter  discharge,  with  a  median  follow-up  period  after  the
rst  BAE  of  757  days  (44--2185  days).
iscussion
n  our  study,  we  found  that  BAE  was  a  safe  and  highly
ffective  procedure  for  hemoptysis  control,  with  acceptable
utcomes.  These  results  are  in  accordance  with  those  pre-
iously  reported.15--18 Although  the  deﬁnition  of  immediate
uccess  of  BAE  varies  in  different  studies,  most  reported  suc-
ess  rates  range  from  80  to  90%.15 In  our  study,  immediate
uccess  was  achieved  in  98.5%  of  our  patients.  Two  recent
etrospectives  studies  reported  a  success  rate  of  96.0%  for
mmediate  control  of  hemoptysis  after  BAE.19,20
Several  deﬁnitions  are  used  for  hemoptysis  severity,
ased  on  the  amount  of  hemoptysis  per  24-hour  period.  In
ur  study,  due  to  lack  of  data  on  the  amount  of  bleeding,
emoptysis  severity  was  based  on  the  same  criteria  used
n  a previous  study  conducted  at  our  centre.14 Using  these
riteria,  almost  half  the  patients  in  our  study  presented  with
evere  hemoptysis,  some  of  them  warranting  an  urgent  BAA
nd  embolisation.
In  agreement  with  Soares  et  al.,14 bronchiectasis  and
uberculosis  sequelae  were  the  main  associated  pul-
onary  diseases  in  our  study.  Three  other  studies  reported
ulmonary  tuberculosis  (active  and  inactive)  and  bronchiec-
asis  as  the  most  common  causes  of  life-threatening
emoptysis.21--23 Another  study  reported  bronchiectasis  and
ung  cancer  (primary  and  metastatic)  as  the  major  etiolo-
ies  of  massive  hemoptysis  warranting  BAE.15 Although  lung
ancer  was  the  third  commonest  cause  of  hemoptysis  in  a
revious  study,14 only  2  (2.3%)  of  the  patients  in  the  present
tudy  who  underwent  BAA  for  embolisation  purposes  had
his  diagnosis.  Mal  et  al.  demonstrated  that  cancer-related
emoptysis  had  the  highest  failure  rate  and  the  worst  long-
erm  results  after  BAE.24 These  ﬁndings  and  other  data
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suggest  that,  in  cancer-related  hemoptysis,  BAE  may  play
a  role  as  a  temporary  measure  prior  to  surgical  resection.
More  recently,  Fugita  et  al.  reported  good  results  for  BAA
as  a  palliative  measure  in  patients  with  advanced  non-small
cell  lung  cancer.25
During  BAA,  in  the  absence  of  an  identiﬁed  bleeding  site,
several  sensitive  ﬁndings  can  localise  the  bleeding  source;
these  include  vascular  hypertrophy  and  tortuosity,  neovas-
cularity,  hypervascularity,  aneurysm  formation  and  shunting
(bronchial  artery  to  pulmonary  vein  or  bronchial  artery  to
pulmonary  artery).  In  our  study,  hypertrophy  and  tortuosity,
hypervascularity  and  shunting  were  the  main  angiographic
ﬁndings.  Lee  et  al.  reported  similar  results.26
Recurrence  of  hemoptysis  after  successful  BAE  is  a
common  problem.  The  causes  include  recanalisation  of
embolised  vessels,  collateral  circulation  that  feeds  the
bleeding  lesion  and  underlying  disease  progression.15 In  our
study,  long-term  follow-up  revealed  a  relatively  high  bleed-
ing  recurrence  (29.8%).  Inconsistent  rebleeding  rates  have
been  reported  in  different  studies.  One  study  reported
rebleeding  in  28.0%  of  cases  after  successful  BAE.27 Fruchter
et  al.  reported  bleeding  recurrence  in  57.7%  of  patients  after
successful  BAE.15 The  recurrence  rates  have  been  postulated
to  have  a  relationship  with  the  aetiology  of  hemopty-
sis.  Lung  cancer,  tuberculosis,  aspergillosis  and  idiopathic
bronchiectasis  are  associated  with  a  high  risk  of  bleeding
recurrence.15,28,29 In  these  cases,  BAE  should  be  considered
as  a  temporary  and  adjuvant  therapy  to  surgery  or  as  a  spe-
ciﬁc  medical  therapy.
In  our  study,  no  signiﬁcant  statistical  relationship  was
found  between  the  aetiology  and  recurrence.  In  cases  of
early  recurrence  following  an  apparently  successful  BAE,
systemic  and  pulmonary  arterial  contribution  should  be
investigated.10,30 The  beneﬁt  of  performing  a  thorough
investigation  and  embolisation  of  non-bronchial  systemic
collaterals  at  initial  presentation  has  been  conﬁrmed,  as
their  presence  has  a  potential  impact  on  recurrence  of
hemoptysis.10 Non-bronchial  systemic  collaterals  were  sys-
tematically  sought  in  44  (50.0%)  of  our  patients.
It  has  also  been  suggested  that  characteristics  of  embolic
agents  affect  the  outcome  of  BAE.  A  variety  of  embolic
materials,  such  as  PVA,  coils,  gelfoams  and  microspheres,
have  been  used  for  selective  bronchial  and  non-bronchial
systemic  arterial  embolisation  in  patients  with  hemoptysis.
Each  material  has  its  own  particular  characteristics,  with
advantages  and  disadvantages.  In  our  study,  PVA  was  by  far
the  most  widely  used  embolic  agent,  so  we  were  unable  to
perform  a  comparison  between  different  embolic  agents.
The  complication  rate  for  BAA  and  BAE  has  dimin-
ished  gradually  over  the  years,  as  a  result  of  technical
(super-selective  technique)  improvements  and  more  appro-
priate  embolic  materials.  The  major  complications  include
transverse  myelitis,  bronchial  infarction,  esophagobronchial
ﬁstula,  ischaemic  colitis,  transient  cortical  blindness  and
stroke.12 Of  these  complications,  the  most  feared  is  anterior
spinal  cord  ischaemia  due  to  the  inadvertent  embolisation
of  a  spinal  artery.  The  incidence  of  spinal  artery  ischaemia
from  BAE  is  reported  as  between  1.4%  and  6.5%.31 Procedure-
related  complications  occurred  in  a  minority  of  patients
in  our  study,  and  were  self-limited.  Anterior  spinal  cord
ischaemia  was  not  recorded  and  all  patients  were  managed
conservatively.37
Since  the  advent  of  BAE,  surgery  has  been  gradually  aban-
oned  and  is  now  used  mainly  in  emergency  scenarios,  but  it
s  still  indicated  in  certain  circumstances.  Currently,  surgery
s  mainly  reserved  for  technical  failure  cases  of  BAE,  early
r  repeated  recurrences  of  hemoptysis  despite  BAE,  or  in
xtreme  situations  where  the  amount  of  bleeding  or  the
atient’s  cardiopulmonary  status  is  deemed  life-threatening
nd  prohibits  transfer  to  an  interventional  radiology  suite
r  precludes  any  related  delays  in  management.5 Only  6.8%
f  our  patients  underwent  surgical  treatment  despite  BAE,
hich  in  part  conﬁrms  the  effectiveness  of  this  technique.
Our  study  has  some  limitations.  The  retrospective  nature
f  the  study  is  the  main  limitation.  The  severity  of  hemop-
ysis  could  not  be  classiﬁed  according  to  the  volume  loss,
hich  may  interfere  with  interpretation  of  the  results  and
ay  limit  possible  comparisons  with  other  studies.  Some
atients  were  lost  to  follow-up.
In  conclusion,  bronchiectasis  (other  than  that  associ-
ted  with  cystic  ﬁbrosis)  and  tuberculosis  sequelae  were
he  major  aetiology  for  hemoptysis.  Our  results  suggest  that
AE  is  a  safe  and  effective  treatment  for  acute  severe  and
hronic  recurrent  hemoptysis,  supporting  the  current  liter-
ture.  In  addition,  bleeding  recurrence  was  relatively  high
nd  was  correlated  with  presence  of  systemic  pulmonary
hunting.
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